Liang Feng1, Keng Bee Yap, Tze Pin Ng. 1. Gerontological Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Department of PsychologicalMedicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Abstract
OBJECTIVE: Among patients with chronic kidney disease (CKD), we investigated the prevalence of depressive symptoms, their impact on mortality and quality of life, and correlates of depressive symptoms. DESIGN: Prospective cohort study, followed up to 4 years. SETTING: General community. PARTICIPANTS: A total of 362 older adults with CKD (Stages 3 and 4 assessed from estimated glomerular filtration rate [eGFR]) drawn from the Singapore Longitudinal Aging Study cohort. MEASUREMENTS: Scores on the Geriatric Depression Scale (GDS) and the prevalence of depressive symptoms (GDS ≥5) and other variables were assessed at baseline, and SF-12 quality of life (QOL) (at 2 years) and mortality determined from 4 years of follow-up. RESULTS: Depressive symptoms were present in 13% of the participants at baseline, and were associated with poorer SF-12 QOL scores (up to 30 percentage point differences). There was a significant association between depressive symptoms and increased mortality risk (odds ratio: 3.17; 95% confidence interval: 1.17-8.61; χ(2) = 5.11; df = 1; p = 0.023), which was statistically significant in unadjusted analysis, but not in multivariate analysis that accounted for covariates (odds ratio: 2.62; 95% confidence interval: 0.77-8.89; χ(2) = 2.37; df = 1; p = 0.13). Baseline cognitive impairment, functional disability, and other chronic illness were significantly associated with both increasing GDS scores and depressive symptoms. No relationship between eGFR and depressive symptoms was observed. CONCLUSION: Depression among individuals with CKD was significantly associated with poorer quality of life, but not with increased mortality in predialysis CKD patients. More prospective studies are needed to establish the effects of depression on adverse CKD outcomes in predialysis CKD patients.
OBJECTIVE: Among patients with chronic kidney disease (CKD), we investigated the prevalence of depressive symptoms, their impact on mortality and quality of life, and correlates of depressive symptoms. DESIGN: Prospective cohort study, followed up to 4 years. SETTING: General community. PARTICIPANTS: A total of 362 older adults with CKD (Stages 3 and 4 assessed from estimated glomerular filtration rate [eGFR]) drawn from the Singapore Longitudinal Aging Study cohort. MEASUREMENTS: Scores on the Geriatric Depression Scale (GDS) and the prevalence of depressive symptoms (GDS ≥5) and other variables were assessed at baseline, and SF-12 quality of life (QOL) (at 2 years) and mortality determined from 4 years of follow-up. RESULTS:Depressive symptoms were present in 13% of the participants at baseline, and were associated with poorer SF-12 QOL scores (up to 30 percentage point differences). There was a significant association between depressive symptoms and increased mortality risk (odds ratio: 3.17; 95% confidence interval: 1.17-8.61; χ(2) = 5.11; df = 1; p = 0.023), which was statistically significant in unadjusted analysis, but not in multivariate analysis that accounted for covariates (odds ratio: 2.62; 95% confidence interval: 0.77-8.89; χ(2) = 2.37; df = 1; p = 0.13). Baseline cognitive impairment, functional disability, and other chronic illness were significantly associated with both increasing GDS scores and depressive symptoms. No relationship between eGFR and depressive symptoms was observed. CONCLUSION:Depression among individuals with CKD was significantly associated with poorer quality of life, but not with increased mortality in predialysis CKDpatients. More prospective studies are needed to establish the effects of depression on adverse CKD outcomes in predialysis CKDpatients.
Authors: Yelba Castellon-Lopez; Kia Skrine Jeffers; O Kenrik Duru; Gerardo Moreno; Tannaz Moin; Jonathan Grotts; Carol M Mangione; Keith C Norris; Ron D Hays Journal: J Gen Intern Med Date: 2020-03-11 Impact factor: 5.128
Authors: Mary Hannan; Alana Steffen; Lauretta Quinn; Eileen G Collins; Shane A Phillips; Ulf G Bronas Journal: J Nephrol Date: 2018-05-25 Impact factor: 3.902
Authors: Jamie L Hamilton; Adam M Brickman; Rosalyn Lang; Goldie S Byrd; Jonathan L Haines; Margaret A Pericak-Vance; Jennifer J Manly Journal: J Int Neuropsychol Soc Date: 2014-05-19 Impact factor: 2.892
Authors: Amy J Kogon; Ji Young Kim; Nina Laney; Jerilynn Radcliffe; Stephen R Hooper; Susan L Furth; Erum A Hartung Journal: Pediatr Nephrol Date: 2019-05-02 Impact factor: 3.714
Authors: Ulla K Seidel; Janine Gronewold; Michaela Volsek; Olga Todica; Andreas Kribben; Heike Bruck; Dirk M Hermann Journal: PLoS One Date: 2014-03-10 Impact factor: 3.240